The study was powered to investigate whether there was a difference from 45% to 60% in 2-year survival rates in patients with early-stage NSCLC treated with induction chemotherapy followed by surgery versus a control group of patients receiving primary surgery.
|Number of pages||1|
|Journal||Journal of Clinical Oncology|
|Publication status||Published - 15 May 2002|
- preoperative chemotherapy
- lung cancer